Details of the Drug

General Information of Drug (ID: DMM39BF)

Drug Name
Mitoxantrone
Synonyms
DHAD; DHAQ; Dihydroxyanthraquinone; MIX; Misostol; Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantronum; Mitozantrone; DHAQ HCl; Mitoxantrone [INN]; Mitozantrone hydrochloride; Mitoxantrone 2HCl; Liposome Encapsulated Mitoxantrone (LEM); Misostol (TN); Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantronum [INN-Latin]; Novantrone (TN); AN-584/42007670; Novantrone(R) (mitoxantrone for injection concentrate); DHAQ (*Diacetate salt*); MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI)
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [1]
Adult acute monocytic leukemia N.A. Approved [1]
Leukemia N.A. Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Non-hodgkin lymphoma 2B33.5 Phase 1/2 [3]
Metastatic prostate carcinoma N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Analgesics
Affected Organisms
Humans and other mammals
ATC Code
L01DB07: Mitoxantrone
L01DB: Anthracyclines and related substances
L01D: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 444.5
Logarithm of the Partition Coefficient (xlogp) 1
Rotatable Bond Count (rotbonds) 12
Hydrogen Bond Donor Count (hbonddonor) 8
Hydrogen Bond Acceptor Count (hbondacc) 10
ADMET Property
Absorption
The drug is poorly absorbed following oral administration []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 7.9 mL/min/kg [5]
Elimination
7% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 75 hours [5]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.7784 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.25% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 12 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 7.5 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Apoptosis Not Available CCND1 OT8HPTKJ [7]
Apoptosis Not Available MYB OTJH64IV [7]
Cytogenetic investigations Not Available TOP1 OT51O0CF [7]
Drug toxicity Not Available EPHX1 OTBKWQER [7]
Chemical Identifiers
Formula
C22H28N4O6
IUPAC Name
1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
Canonical SMILES
C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
InChI
InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
InChIKey
KKZJGLLVHKMTCM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4212
ChEBI ID
CHEBI:50729
CAS Number
65271-80-9
UNII
BZ114NVM5P
DrugBank ID
DB01204
TTD ID
D0R3JB
VARIDT ID
DR00269
INTEDE ID
DR1102
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN ; TOP2B_HUMAN Modulator [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
ATP-binding cassette sub-family A member 3 (ABCA3) DT2T6VQ ABCA3_HUMAN Substrate [9]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [10]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [11]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [12]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2E1 (CYP2E1)
Main DME 		DEVDYN7 CP2E1_HUMAN Substrate [13]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (AGPAT5) OTNY3VMD PLCE_HUMAN Drug Response [14]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (PLCB4) OTPA0QHW PLCB4_HUMAN Drug Response [14]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Drug Response [14]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Drug Response [14]
3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1) OTQRET2B S5A1_HUMAN Drug Response [14]
Actin, alpha skeletal muscle (ACTA1) OTOVGLPG ACTS_HUMAN Gene/Protein Processing [15]
Actin, gamma-enteric smooth muscle (ACTG2) OTRDWUO0 ACTH_HUMAN Drug Response [14]
ADP-ribose glycohydrolase MACROD1 (MACROD1) OTWFEVRW MACD1_HUMAN Drug Response [14]
Aldehyde dehydrogenase, mitochondrial (ALDH2) OTKJ9I3N ALDH2_HUMAN Drug Response [14]
AN1-type zinc finger protein 1 OTGZ9X6J ZFAN1_HUMAN Drug Response [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 2.4479 6.9829 -0.4329 10.3671
SK-ES-1 GDSC2 -6.2212 -2.5304 -6.2532 74.3805
EW-3 GDSC2 -5.4021 -1.8828 -5.4425 67.9925
HuO9 GDSC2 -5.2722 -3.0224 -5.2747 68.3425
EW-16 GDSC2 -5.2144 -1.9092 -5.2468 66.6591
SK-PN-DW GDSC2 -4.9965 -3.153 -4.9972 65.9012
ES8 GDSC2 -4.9933 -1.798 -5.0245 64.8144
ES7 GDSC2 -4.5335 -2.0579 -4.5433 61.0829
EW-22 GDSC2 -4.5002 -2.5015 -4.5024 60.949
EW-1 GDSC2 -2.8031 0.1557 -2.9028 44.3309
A-673 GDSC2 -2.2061 2.8959 -2.9721 40.6257
NY GDSC2 -1.8215 5.748 -3.7376 40.3166
TC-71 GDSC2 -1.5103 1.7117 -1.8284 32.6088
EW-13 GDSC2 -1.4672 2.8516 -2.161 33.8382
EW-11 GDSC2 -1.4614 3.623 -2.4548 34.9465
CAL-78 GDSC2 -1.173 2.6053 -1.7544 30.5797
ES4 GDSC2 -0.9658 3.4574 -1.8652 30.108
MHH-ES-1 GDSC2 -0.607 4.0849 -1.7607 28.0028
HOS GDSC2 -0.1764 4.3584 -1.4482 24.6392
EW-24 GDSC2 -0.1065 4.8239 -1.5949 25.1016
EW-7 GDSC2 0.3048 6.5012 -2.0073 25.4896
HuO-3N1 GDSC2 0.5378 5.1898 -1.1504 20.3123
MG-63 GDSC2 0.7569 3.2593 -0.0133 12.8118
CADO-ES1 GDSC2 0.9096 2.8633 0.3223 10.2019
CAL-72 GDSC2 0.9551 8.258 -2.2899 24.4763
SaOS-2 GDSC2 1.0752 4.4814 -0.3073 13.5154
U2OS GDSC2 1.2854 4.5961 -0.177 12.0335
ES5 GDSC2 1.5644 9.5207 -2.4001 23.0311
NOS-1 [Human HNSCC] GDSC2 2.0464 4.5793 0.4528 5.9319
H-EMC-SS GDSC2 2.4001 7.46 -0.704 12.0751
ES6 GDSC2 2.7985 6.8777 -0.1311 7.7575
CHSA8926 GDSC2 2.8383 8.3316 -0.8094 11.6006
EW-18 GDSC2 2.8578 5.3125 0.6448 3.1122
G-292 clone A141B1 GDSC2 3.27 5.7075 0.7008 2.2036
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OACM5.1 C GDSC2 -3.6314 0.3444 -3.8234 52.0649
FLO-1 GDSC2 -3.4276 0.4618 -3.6248 50.2676
KYSE-220 GDSC2 -0.2305 4.4676 -1.5524 25.3912
ESO-26 GDSC2 0.2246 3.0294 -0.4445 17.4284
ESO-51 GDSC2 1.242 2.7188 0.7119 6.6128
KYSE-50 GDSC2 2.7054 11.9296 -2.6858 21.0511
TE-12 GDSC2 2.9973 10.9359 -1.972 17.2105
OACP4 C GDSC2 3.04 6.3501 0.2783 4.8688
KYAE-1 GDSC2 4.2196 6.0585 0.9871 0.3531
SK-GT-4 GDSC2 4.374 12.3143 -1.6713 12.7301
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC2 2.0704 5.0696 0.2288 7.2679
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IMR-5 GDSC2 -6.011 -4.1089 -6.0113 75.6825
CHP-212 GDSC2 -3.9031 3.6151 -5.0598 53.1516
NH-12 GDSC2 -3.892 0.0309 -4.0509 54.3821
SJNB-10 GDSC2 -3.6797 -0.8733 -3.7205 52.7186
Kelly GDSC2 -3.5581 0.2509 -3.7279 51.4386
SJNB-14 GDSC2 -2.9416 2.5214 -3.6391 46.5154
SJNB-13 GDSC2 -2.6571 1.6889 -3.0734 43.698
SK-N-DZ GDSC2 -2.2804 5.8133 -4.2357 43.4285
SiMa GDSC2 -2.0642 3.9369 -3.2181 40.4288
NB69 GDSC2 -1.9716 2.3665 -2.5348 37.9607
NB(TU)1 GDSC2 -1.8725 5.92 -3.8662 40.8166
CHP-134 GDSC2 -1.2148 5.3317 -2.9353 35.3737
SK-N-AS GDSC2 -0.5869 5.7406 -2.4965 31.0681
GI-ME-N GDSC2 0.1595 2.4539 -0.2713 16.6843
KP-N-YN GDSC2 1.1791 13.1549 -4.5416 31.2538
TGW GDSC2 1.4579 7.5034 -1.4808 19.0206
SK-N-BE(2)-M17 GDSC2 1.8357 9.1134 -1.9724 20.3175
GOTO GDSC2 2.0697 4.7919 0.3653 6.4196
SJNB-7 GDSC2 2.8717 5.3478 0.637 3.1323
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC2 2.2074 6.2529 -0.2528 9.888
Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU4475 GDSC2 -5.3807 -1.9586 -5.4159 67.9521
CAL-51 GDSC2 -3.6041 1.8216 -4.1443 51.5857
AU565 GDSC2 -1.3934 2.1746 -1.8436 32.0843
MDA-MB-468 GDSC2 -1.0294 4.9147 -2.5601 33.2513
Hs 578T GDSC2 -0.6945 2.9558 -1.3761 26.4804
MDA-MB-231 GDSC2 -0.5751 2.639 -1.1255 24.6256
HCC1143 GDSC2 0.0732 3.7919 -0.9391 20.884
Evsa-T GDSC2 0.3014 8.5612 -3.0231 29.5633
MDA-MB-453 GDSC2 0.3886 4.6508 -1.0315 20.1961
MDA-MB-415 GDSC2 1.0277 3.1086 0.3204 9.7887
BT-549 GDSC2 1.0892 5.4026 -0.7512 16.1413
HCC1187 GDSC2 1.3234 2.3577 0.9637 4.7665
HCC2157 GDSC2 1.3431 3.1672 0.5842 7.0762
HCC1569 GDSC2 1.6097 4.453 0.1715 8.8721
HCC1954 GDSC2 1.8147 11.3693 -3.1172 25.1138
HCC38 GDSC2 1.8635 6.4538 -0.6214 13.0258
EFM-192A GDSC2 1.9215 5.8053 -0.2518 10.6349
CAL-120 GDSC2 1.9455 5.5464 -0.1039 9.6596
HCC1419 GDSC2 1.9836 4.0237 0.6797 4.6714
JIMT-1 GDSC2 2.0476 5.1488 0.1723 7.6772
MDA-MB-436 GDSC2 2.0716 10.0777 -2.2629 20.9648
HCC1806 GDSC2 2.0895 4.9331 0.3105 6.7115
T-47D GDSC2 2.1029 8.3644 -1.3834 16.628
HDQ-P1 GDSC2 2.138 4.6028 0.5084 5.3658
MRK-nu-1 GDSC2 2.272 4.2275 0.7831 3.3927
HCC1428 GDSC2 2.3077 3.7918 1.0099 1.9987
MDA-MB-157 GDSC2 2.3163 6.9914 -0.5356 11.3049
MFM-223 GDSC2 2.3268 4.96 0.4686 5.179
CAMA-1 GDSC2 2.408 5.596 0.2171 6.532
BT-20 GDSC2 2.7304 5.9951 0.2459 5.661
CAL-85-1 GDSC2 2.8152 8.1221 -0.7237 11.171
OCUB-M GDSC2 2.9124 10.2561 -1.7001 16.1199
COLO 824 GDSC2 2.9228 7.0397 -0.1241 7.449
MDA-MB-330 GDSC2 2.9981 6.9419 -0.0272 6.7238
BT-474 GDSC2 3.2088 4.822 1.0369 0.7655
ZR-75-30 GDSC2 3.2788 7.5692 -0.1408 6.8217
MDA-MB-361 GDSC2 3.3705 7.1952 0.0914 5.3319
HCC1500 GDSC2 3.4202 5.8316 0.7258 1.8953
MCF-7 GDSC2 3.5463 11.7934 -1.9914 15.9999
HCC1937 GDSC2 3.8953 5.5251 1.0545 0.3233
HCC70 GDSC2 4.0317 6.1371 0.8842 0.7206
EFM-19 GDSC2 4.1689 6.5236 0.7951 0.9239
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Daoy GDSC2 -4.3409 -0.9216 -4.4085 58.6861
D283 Med GDSC2 -2.271 1.0468 -2.4894 39.5677
U-251MG GDSC2 -2.1687 2.699 -2.862 40.1106
SF539 GDSC2 -1.9666 2.5851 -2.6037 38.1623
H4 GDSC2 -1.5166 6.5476 -3.7924 39.0066
AM-38 GDSC2 -0.8877 2.7443 -1.4997 27.9895
8-MG-BA GDSC2 -0.1432 3.4536 -1.0078 22.1398
GB-1 GDSC2 -0.04 5.3388 -1.773 25.7091
Becker GDSC2 0.1077 6.0362 -1.9662 26.0418
U-87MG ATCC GDSC2 0.1211 3.4332 -0.7287 19.4934
M059J GDSC2 0.248 6.1237 -1.8763 25.0941
SK-MG-1 GDSC2 0.2705 3.3179 -0.5255 17.7225
GI-1 GDSC2 0.8534 4.1847 -0.3656 14.6208
SF268 GDSC2 0.8544 5.5002 -1.0104 18.4202
PFSK-1 GDSC2 0.8695 5.415 -0.9547 18.0522
GaMG GDSC2 0.951 5.8409 -1.0919 18.5517
ONS-76 GDSC2 0.9598 6.1759 -1.2503 19.3943
KS-1 [Human Krukenberg tumour] GDSC2 1.1245 6.3217 -1.1773 18.4524
DK-MG GDSC2 1.1697 2.2429 0.868 5.9112
YH-13 GDSC2 1.1755 5.3503 -0.649 15.2573
DBTRG-05MG GDSC2 1.2647 7.5706 -1.6787 20.6316
KALS-1 GDSC2 1.2934 4.7008 -0.2222 12.2885
U-118MG GDSC2 1.3579 4.7292 -0.1802 11.827
A-172 GDSC2 1.365 7.4904 -1.553 19.681
CAS-1 GDSC2 1.4679 8.6725 -2.0568 21.8071
LN-18 GDSC2 1.4826 4.5364 0.0231 10.1792
T98G GDSC2 1.8097 3.4078 0.8534 4.0181
42-MG-BA GDSC2 2.0308 6.1911 -0.3579 10.9872
D-263MG GDSC2 2.0981 4.788 0.3884 6.2061
LN-229 GDSC2 2.3666 5.7819 0.0969 7.3625
LN-405 GDSC2 2.5225 5.6716 0.2604 6.0139
SW1088 GDSC2 2.8354 7.5154 -0.4138 9.3393
D-392MG GDSC2 3.2523 9.9775 -1.316 13.3702
KINGS-1 GDSC2 3.8431 13.9579 -2.8354 18.9284
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC2 2.424 7.1587 -0.5373 11.0429
TGBC24TKB GDSC2 3.486 8.7445 -0.5614 8.7864
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ESS-1 GDSC2 -3.8531 -2.4166 -3.8535 54.567
RL95-2 GDSC2 -1.2736 3.336 -2.141 32.7853
AN3-CA GDSC2 -0.1516 3.5211 -1.0461 22.3862
MFE-319 GDSC2 1.6589 2.9259 0.9751 3.6514
MFE-296 GDSC2 1.9052 4.022 0.6219 5.2272
KLE GDSC2 2.6171 5.0095 0.6374 3.5782
EN GDSC2 3.0376 4.8468 0.9465 1.3067
MFE-280 GDSC2 3.248 6.0364 0.5448 3.0396
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 128 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MOLT-16 GDSC2 -8.0618 -6.8092 -8.0618 94.2177
SU-DHL-5 GDSC2 -7.7316 -6.6438 -7.7316 92.3059
MOLM-13 GDSC2 -7.1207 -4.9701 -7.121 84.9682
SK-MM-2 GDSC2 -6.8183 -4.5827 -6.8188 82.3377
P12-Ichikawa GDSC2 -6.2564 -4.2351 -6.2567 77.8156
KOPN-8 GDSC2 -6.1862 -4.152 -6.1866 77.1557
DoHH2 GDSC2 -6.1658 -5.1576 -6.1658 77.7433
ALL-PO GDSC2 -6.0321 -2.8366 -6.0475 73.8666
NALM-6 GDSC2 -6.0098 -4.3386 -6.0099 75.8837
CTV-1 GDSC2 -5.9204 -3.786 -5.9213 74.5759
HC-1 GDSC2 -5.8161 -2.6359 -5.8334 72.0762
SR GDSC2 -5.8006 -3.4117 -5.803 73.1541
ALL-SIL GDSC2 -5.7741 -3.4076 -5.7764 72.9395
MM1.S GDSC2 -5.7037 -3.345 -5.7061 72.2993
SUP-M2 GDSC2 -5.5243 -4.6872 -5.5243 71.3402
Hs 445 GDSC2 -5.4744 2.0241 -6.2434 62.744
KY821 GDSC2 -5.4379 -3.4777 -5.4386 70.1534
MHH-CALL-2 GDSC2 -5.389 -4.2895 -5.389 69.9716
SCC-3 GDSC2 -5.3887 -4.5042 -5.3887 69.979
RS4;11 GDSC2 -5.3389 -3.4984 -5.3393 69.2637
CESS GDSC2 -5.3319 -2.2396 -5.3524 67.9821
EoL-1 GDSC2 -5.2727 -3.9229 -5.2728 68.7787
MOLT-13 GDSC2 -5.2071 -1.7968 -5.2456 66.4572
BL-41 GDSC2 -5.1742 -2.715 -5.1795 67.233
697 GDSC2 -5.1636 -2.551 -5.1717 66.9907
Daudi GDSC2 -5.1402 -1.7978 -5.1763 65.9554
EB2 GDSC2 -5.0612 -3.4522 -5.0614 66.6174
JSC-1 GDSC2 -5.026 -0.9931 -5.1235 64.0901
SUP-B15 GDSC2 -4.9908 -3.6455 -4.9908 65.9642
P30/OHK GDSC2 -4.9746 -2.8784 -4.9766 65.57
IM-9 GDSC2 -4.9543 -2.8613 -4.9563 65.3736
CML-T1 GDSC2 -4.9485 -3.7041 -4.9485 65.5511
Raji GDSC2 -4.8401 -3.4544 -4.8401 64.4531
DEL GDSC2 -4.8116 -3.0344 -4.8122 64.0951
RPMI-6666 GDSC2 -4.8044 -2.1206 -4.8174 63.5438
ML-2 GDSC2 -4.8007 0.8156 -5.1899 60.4559
BALL-1 GDSC2 -4.7381 -2.9375 -4.7389 63.3606
JVM-2 GDSC2 -4.6504 -1.7271 -4.6747 61.9091
WSU-NHL GDSC2 -4.6474 -2.5841 -4.6498 62.3789
GA-10 GDSC2 -4.5615 0.6173 -4.8855 59.0915
SU-DHL-8 GDSC2 -4.4725 -2.816 -4.473 60.7474
ATN-1 GDSC2 -4.4078 -3.2714 -4.4078 60.1357
L-540 GDSC2 -4.3489 -0.5056 -4.4628 58.4579
BC-1 GDSC2 -4.2209 -1.3959 -4.2487 57.9045
P32/ISH GDSC2 -4.1804 -3.0284 -4.1804 57.8539
WIL2 NS GDSC2 -4.0501 -2.6065 -4.0503 56.5406
Jurkat GDSC2 -4.0184 -3.2134 -4.0184 56.2303
Reh GDSC2 -3.956 -2.7019 -3.9561 55.6025
KE-37 GDSC2 -3.8774 -1.8451 -3.8824 54.769
RPMI-8866 GDSC2 -3.8679 -1.4714 -3.8825 54.6203
Namalwa GDSC2 -3.8544 -0.596 -3.9282 54.272
H9 GDSC2 -3.8409 -0.4525 -3.9297 54.1063
TUR GDSC2 -3.704 -1.5942 -3.7118 53.0408
CCRF-CEM GDSC2 -3.687 -1.4331 -3.6989 52.8591
OCI-AML-2 GDSC2 -3.6563 -1.4192 -3.6681 52.5576
OCI-AML-3 GDSC2 -3.6364 -0.3164 -3.7289 52.2255
ARH-77 GDSC2 -3.6139 -1.2081 -3.6327 52.1253
JURL-MK1 GDSC2 -3.3462 -1.6345 -3.349 49.4864
HAL-01 GDSC2 -3.3409 -1.107 -3.3568 49.4402
MOLP-8 GDSC2 -3.2737 3.4576 -4.3252 49.1657
OCI-M1 GDSC2 -3.1138 -0.1986 -3.1885 47.2837
JVM-3 GDSC2 -3.111 0.2795 -3.2515 47.3445
LC4-1 GDSC2 -3.1107 -1.1444 -3.1201 47.1436
Karpas-231 GDSC2 -3.0494 -1.4572 -3.0518 46.5141
A3/Kawakami GDSC2 -3.0436 -0.7691 -3.067 46.506
KMS-12-BM GDSC2 -2.9893 0.2269 -3.1126 46.1697
Granta-519 GDSC2 -2.9848 1.5846 -3.402 46.553
SKM-1 GDSC2 -2.9469 -1.6506 -2.9474 45.4799
A4/Fukuda GDSC2 -2.9163 -0.1937 -2.9801 45.3444
DND-41 GDSC2 -2.898 -0.2676 -2.9533 45.1447
SUP-T1 GDSC2 -2.8816 0.9961 -3.1423 45.4105
L-428 GDSC2 -2.8506 -0.3804 -2.8933 44.6456
MLMA GDSC2 -2.739 1.7703 -3.1857 44.4767
RC-K8 GDSC2 -2.7061 2.5197 -3.3829 44.5966
OCI-AML-5 GDSC2 -2.6214 -0.1168 -2.6769 42.42
DG-75 GDSC2 -2.5825 1.9442 -3.0661 43.1858
SUP-HD1 GDSC2 -2.5412 0.9895 -2.7705 42.1776
BE-13 GDSC2 -2.515 2.1214 -3.0467 42.704
ST486 GDSC2 -2.497 1.2562 -2.7845 41.9275
Karpas-422 GDSC2 -2.4078 0.1861 -2.4854 40.388
PF-382 GDSC2 -2.3191 2.0444 -2.8095 40.8695
MHH-PREB-1 GDSC2 -2.2603 -0.9393 -2.2623 38.5975
HL-60 GDSC2 -2.2435 -1.4729 -2.2435 38.4189
HEL GDSC2 -2.2408 0.3414 -2.3281 38.775
AMO1 GDSC2 -2.1734 2.5182 -2.8048 39.9766
Kasumi-1 GDSC2 -2.1668 1.8006 -2.5703 39.2152
LAMA-84 GDSC2 -2.0993 2.8428 -2.8379 39.6385
EM-2 GDSC2 -1.9845 0.6213 -2.0961 36.3389
CA46 GDSC2 -1.921 2.0016 -2.3625 37.0602
Ku812 GDSC2 -1.9036 0.6752 -2.018 35.5492
TK [Human B-cell lymphoma] GDSC2 -1.8407 0.0889 -1.8755 34.548
NCI-H929 GDSC2 -1.8335 2.2735 -2.3541 36.5412
SU-DHL-10 GDSC2 -1.7745 0.0946 -1.8067 33.8719
VAL GDSC2 -1.6632 2.3181 -2.1841 34.9552
VL51 GDSC2 -1.5221 2.768 -2.1893 34.2362
KMOE-2 GDSC2 -1.4126 2.3646 -1.9282 32.5643
NOMO-1 GDSC2 -1.3664 0.7323 -1.4496 30.0373
Jiyoye GDSC2 -1.2624 3.2538 -2.0965 32.5437
KG-1 GDSC2 -1.1716 1.0856 -1.3032 28.3344
DB GDSC2 -1.1603 2.4367 -1.6804 30.1665
Karpas-299 GDSC2 -1.1247 4.7525 -2.585 33.7816
MN-60 GDSC2 -1.0583 4.1438 -2.2509 32.2005
GR-ST GDSC2 -1.0279 5.5153 -2.8303 34.1827
RPMI-8226 GDSC2 -0.9653 3.3833 -1.8343 29.9637
KM-H2 GDSC2 -0.9154 6.3205 -3.0911 34.5196
Farage GDSC2 -0.8087 9.852 -4.6807 37.9434
EJM GDSC2 -0.6811 2.1003 -1.0457 24.6719
Loucy GDSC2 -0.5853 6.2162 -2.7186 31.8832
GDM-1 GDSC2 -0.5521 2.3374 -0.9888 23.7834
SU-DHL-6 GDSC2 -0.0509 2.9929 -0.7141 20.1045
OPM-2 GDSC2 -0.0298 3.7269 -1.0135 21.7112
U-698-M GDSC2 0.1984 3.4341 -0.6508 18.7372
Karpas-620 GDSC2 0.2764 3.715 -0.7005 18.7237
MEG-01 GDSC2 0.3811 7.1624 -2.2612 26.3325
Karpas-45 GDSC2 0.4559 3.5445 -0.4432 16.525
JJN-3 GDSC2 0.6158 2.614 0.1392 12.4266
Ramos.2G6.4C10 GDSC2 0.7256 1.4707 0.6756 8.884
L-363 GDSC2 0.7393 9.6658 -3.1802 28.6163
KCL-22 GDSC2 0.7588 3.5731 -0.1602 13.7013
Karpas-1106P GDSC2 1.3595 7.5318 -1.5783 19.8271
MOLT-4 GDSC2 1.8226 3.3878 0.8731 3.8614
HDLM-2 GDSC2 1.8505 4.0913 0.5456 5.8477
U266B1 GDSC2 2.012 7.299 -0.9245 14.3701
L-1236 GDSC2 2.2139 7.9382 -1.0839 14.7114
K-562 GDSC2 2.5246 5.3078 0.4364 4.9488
LP-1 GDSC2 3.4027 5.0441 1.0351 0.6305
HH [Human lymphoma] GDSC2 4.2155 6.3937 0.8635 0.6768
ME1 GDSC2 5.4864 19.6934 -4.46 21.1225
⏷ Show the Full List of 128 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ACHN GDSC2 -1.9294 1.8592 -2.3286 36.9796
LB996-RCC GDSC2 -1.8463 5.0574 -3.4595 39.8418
KMRC-20 GDSC2 -1.3689 5.521 -3.1765 36.8052
CAL-54 GDSC2 -0.6687 8.2112 -3.7531 35.365
786-O GDSC2 -0.4329 4.1314 -1.6038 26.4922
SW13 GDSC2 0.5754 2.8994 -0.0285 13.5859
SN12C GDSC2 1.2453 4.5846 -0.2065 12.3433
769-P GDSC2 1.3873 7.298 -1.4379 19.0155
OS-RC-2 GDSC2 1.6191 3.1281 0.8417 4.608
BFTC-909 GDSC2 1.7917 8.0237 -1.4638 17.9328
HA7-RCC GDSC2 1.9063 6.0266 -0.3741 11.4225
A-498 GDSC2 1.9324 5.9101 -0.2954 10.8719
RCC10RGB GDSC2 2.2493 6.0136 -0.103 8.87
TK-10 GDSC2 2.5019 11.2243 -2.4935 20.7872
NCC010 GDSC2 2.7845 5.4578 0.5335 3.8697
KTCTL-195 GDSC2 2.8555 15.4197 -4.3042 26.2256
RXF 393L GDSC2 3.063 7.9497 -0.4657 9.1339
A-704 GDSC2 3.7945 5.8759 0.8835 0.8805
VMRC-RCZ GDSC2 3.9095 5.9323 0.9107 0.7116
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCT 15 GDSC2 -1.4432 3.2435 -2.2846 34.2112
KM12 GDSC2 -1.3713 1.6447 -1.6578 31.0956
SK-CO-1 GDSC2 -0.9357 1.2422 -1.0804 26.0424
SW48 GDSC2 -0.5357 4.7224 -1.9746 28.681
HCC2998 GDSC2 -0.1373 4.318 -1.3905 24.1815
SW620 GDSC2 0.2782 5.5385 -1.5641 23.4563
GP5d GDSC2 0.671 6.0862 -1.4663 21.5307
HT-55 GDSC2 0.767 3.0092 0.1135 12.0025
SNU-C5 GDSC2 0.8519 4.8916 -0.713 16.71
SNU-175 GDSC2 0.8574 6.4675 -1.4863 20.991
HT-29 GDSC2 0.8711 5.6201 -1.0546 18.6121
LS513 GDSC2 0.908 7.2506 -1.83 22.5367
SNU-C1 GDSC2 0.9939 4.9384 -0.6066 15.5987
HCT 116 GDSC2 1.15 4.7843 -0.3902 13.7785
NCI-H716 GDSC2 1.2971 6.2527 -0.9929 16.8702
LS180 GDSC2 1.4462 5.9347 -0.7066 14.7508
RKO GDSC2 1.4981 6.6034 -0.997 16.2721
LS411N GDSC2 1.5326 5.1139 -0.2233 11.565
LoVo GDSC2 1.5935 6.1703 -0.7006 14.2728
RCM-1 [Human ESC] GDSC2 1.6812 4.6746 0.1196 8.9936
CaR-1 GDSC2 1.7309 3.5108 0.7408 4.9354
SNU-61 GDSC2 1.7613 3.3533 0.8431 4.2087
SNU-1040 GDSC2 2.125 4.1042 0.7421 3.956
SW1463 GDSC2 2.1906 8.1193 -1.1923 15.367
HT115 GDSC2 2.2239 6.5308 -0.3778 10.601
LS123 GDSC2 2.3461 7.7269 -0.877 13.2046
COLO205 GDSC2 2.3536 5.3438 0.3012 6.1421
C2BBe1 GDSC2 2.3574 6.7218 -0.3716 10.2258
SW948 GDSC2 2.4511 4.4716 0.7838 3.0381
DiFi GDSC2 2.5649 8.039 -0.8663 12.586
SW1116 GDSC2 2.628 4.9098 0.6905 3.2521
T84 GDSC2 2.6539 5.079 0.6281 3.5638
SNU-C2B GDSC2 2.743 9.4846 -1.4462 15.2671
CL-11 GDSC2 2.7898 6.4881 0.0502 6.6998
CCK-81 GDSC2 2.7911 5.7567 0.3982 4.6422
COLO 678 GDSC2 2.7956 5.1524 0.6807 3.0162
SW626 GDSC2 2.816 7.9137 -0.6213 10.5848
SW837 GDSC2 2.8262 5.3146 0.625 3.2763
SW1417 GDSC2 2.8315 4.7018 0.9018 1.7766
CW-2 GDSC2 3.1512 6.7271 0.1724 5.2701
NCI-H747 GDSC2 3.4163 6.2973 0.5232 2.9074
SNU-81 GDSC2 3.5222 5.3556 0.9666 0.7837
LS1034 GDSC2 4.101 5.694 1.0713 0.2228
COLO 320HSR GDSC2 4.1748 5.8716 1.0363 0.2663
MDST8 GDSC2 4.3932 12.5046 -1.7492 13.0592
SNU-407 GDSC2 4.4626 12.3646 -1.6366 12.3901
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC2 2.0579 4.4202 0.5396 5.3637
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-4 GDSC2 -0.453 2.5892 -0.976 23.2764
HLE GDSC2 -0.415 3.5613 -1.3348 25.0438
SNU-387 GDSC2 -0.403 5.643 -2.2703 29.398
SNU-398 GDSC2 -0.1625 6.2394 -2.3213 28.6378
SK-HEP-1 GDSC2 0.0962 3.2212 -0.6603 19.1977
JHH-6 GDSC2 0.4533 4.186 -0.7473 18.3296
SNU-423 GDSC2 1.5714 8.1634 -1.7155 19.864
HuH-1 GDSC2 1.5789 8.6986 -1.9769 21.0992
JHH-1 GDSC2 1.95 4.0343 0.6496 4.9419
JHH-2 GDSC2 2.1168 4.4459 0.5699 5.0356
Hep 3B2.1-7 GDSC2 2.3302 4.9877 0.4575 5.2391
Hep-G2/C3A GDSC2 2.4291 3.9477 1.0108 1.7922
JHH-7 GDSC2 3.5594 12.9553 -2.5504 18.4187
Huh-7 GDSC2 4.1772 6.1557 0.9359 0.494
SNU-449 GDSC2 4.2148 5.988 1.0102 0.3054
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 129 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1623 GDSC2 -4.2595 -0.934 -4.3219 57.9992
NCI-H1651 GDSC2 -4.2033 3.6572 -5.3983 54.8548
NCI-H1155 GDSC2 -3.8999 0.4442 -4.1324 54.2839
HCC78 GDSC2 -3.7341 1.2201 -4.1245 52.7078
NCI-H209 GDSC2 -3.6747 -1.0179 -3.7055 52.6916
NCI-H82 GDSC2 -3.5918 0.4159 -3.7937 51.7106
A-549 GDSC2 -3.4443 2.4515 -4.1626 50.3427
NCI-H1781 GDSC2 -3.2346 0.2378 -3.3777 48.499
LXF 289 GDSC2 -3.0714 2.8241 -3.8819 47.6125
NCI-H1048 GDSC2 -2.8648 1.044 -3.1349 45.2742
NCI-H2122 GDSC2 -2.7901 2.0268 -3.3172 45.0534
NCI-H1876 GDSC2 -2.7247 -0.0283 -2.7958 43.4877
NCI-H1792 GDSC2 -2.7244 2.4537 -3.3809 44.7137
SBC-5 GDSC2 -2.5742 -0.2614 -2.6139 41.896
NCI-H1694 GDSC2 -2.55 -0.198 -2.594 41.6714
NCI-H2795 GDSC2 -2.1937 6.7606 -4.5693 43.4487
DMS 79 GDSC2 -2.0714 2.3711 -2.6447 38.8949
SBC-3 GDSC2 -1.9806 1.7446 -2.351 37.3547
NCI-H2228 GDSC2 -1.66 5.0484 -3.2638 38.4391
NCI-H526 GDSC2 -1.5713 0.9044 -1.7004 32.3129
EMC-BAC-2 GDSC2 -1.4653 5.9954 -3.4884 38.0716
Lu-99A GDSC2 -1.2608 8.1824 -4.307 38.9636
LCLC-103H GDSC2 -1.0979 1.8805 -1.4287 28.6208
NCI-H446 GDSC2 -1.0943 1.2539 -1.2557 27.7153
NCI-H2170 GDSC2 -1.0602 1.4358 -1.2625 27.5865
NCI-H2373 GDSC2 -0.9114 3.4815 -1.818 29.6386
NCI-H2023 GDSC2 -0.7464 2.0231 -1.0912 25.2141
NCI-H1944 GDSC2 -0.7396 4.5116 -2.0854 30.0568
NCI-H2810 GDSC2 -0.6587 4.7225 -2.0985 29.7579
LOU-NH91 GDSC2 -0.6437 3.745 -1.6503 27.6329
NCI-H2227 GDSC2 -0.6388 9.6062 -4.402 36.7654
NCI-H3122 GDSC2 -0.6269 3.7826 -1.6493 27.554
HOP-62 GDSC2 -0.5326 2.8377 -1.1575 24.6103
EPLC-272H GDSC2 -0.4721 3.028 -1.17 24.4137
NCI-H2804 GDSC2 -0.3972 3.6339 -1.3479 25.0367
SW1573 GDSC2 -0.1078 4.9859 -1.6722 25.4892
DMS 273 GDSC2 -0.1039 5.0309 -1.6895 25.5585
SW1271 GDSC2 0.0107 4.525 -1.3397 23.3232
COR-L23 GDSC2 0.145 4.6776 -1.2799 22.4808
DMS 53 GDSC2 0.1922 5.6902 -1.7189 24.5504
NCI-H2722 GDSC2 0.2151 6.3667 -2.0254 25.9054
NCI-H1975 GDSC2 0.262 3.5295 -0.6299 18.3677
Calu-6 GDSC2 0.3303 5.294 -1.3966 22.3978
Lu-135 GDSC2 0.3451 5.9905 -1.7206 23.9867
EBC-1 GDSC2 0.3578 3.3982 -0.4738 17.0798
NCI-H23 GDSC2 0.3969 4.8574 -1.1227 20.6738
Ms-1 GDSC2 0.4614 4.7979 -1.0326 19.9345
COR-L311 GDSC2 0.4636 3.8843 -0.5946 17.3944
NCI-H522 GDSC2 0.4873 6.4913 -1.8339 24.0162
IST-SL2 GDSC2 0.489 2.2805 0.1468 12.8938
LCLC-97TM1 GDSC2 0.4957 2.6699 -0.0089 13.781
HARA [Human squamous cell lung carcinoma] GDSC2 0.5849 10.6925 -3.827 31.1408
SK-LU-1 GDSC2 0.6717 4.9684 -0.9173 18.5241
NCI-H322M GDSC2 0.7049 4.8545 -0.8307 17.9079
PC-14 GDSC2 0.7549 5.795 -1.2464 20.0701
NCI-H2461 GDSC2 0.822 7.2981 -1.9299 23.3013
NCI-H211 GDSC2 0.9058 7.0684 -1.7415 22.1141
NCI-H520 GDSC2 0.9317 6.1218 -1.2485 19.4789
NCI-H2369 GDSC2 0.9325 2.5572 0.4866 9.1168
NCI-H2595 GDSC2 0.9897 6.3025 -1.2866 19.4908
NCI-H1650 GDSC2 1.0173 5.9067 -1.0655 18.1832
RERF-LC-Sq1 GDSC2 1.0394 6.4595 -1.3206 19.5092
Calu-3 GDSC2 1.0654 6.9263 -1.5302 20.5231
NCI-H226 GDSC2 1.1171 3.7735 0.0799 10.9783
Lu-139 GDSC2 1.1223 8.1564 -2.0938 23.0628
COLO 668 GDSC2 1.1654 4.4181 -0.1949 12.5278
NCI-H661 GDSC2 1.1675 3.007 0.5018 8.1762
NCI-H1693 GDSC2 1.179 4.393 -0.1703 12.3315
HCC44 GDSC2 1.2503 4.5436 -0.1818 12.1745
CPC-N GDSC2 1.3024 4.4942 -0.1113 11.5722
NCI-H1793 GDSC2 1.5824 5.4892 -0.3693 12.3153
UMC-11 GDSC2 1.6285 5.015 -0.094 10.4808
NCI-H596 GDSC2 1.6961 7.7968 -1.4289 18.0314
NCI-H2029 GDSC2 1.7233 3.3875 0.7962 4.6062
NCI-H810 GDSC2 1.7307 6.562 -0.7832 14.3543
NCI-H2731 GDSC2 1.7423 4.4412 0.2858 7.7765
NCI-H1092 GDSC2 1.7595 4.7594 0.1407 8.6412
HCC366 GDSC2 1.7609 5.3283 -0.1421 10.4026
NCI-H513 GDSC2 1.8084 5.4064 -0.1429 10.2746
NCI-H3255 GDSC2 1.8239 6.3308 -0.5919 12.9619
SHP-77 GDSC2 1.8661 3.9895 0.6082 5.4133
Lu-65 GDSC2 1.8883 6.812 -0.7803 13.8877
NCI-H2085 GDSC2 1.8933 7.4776 -1.1085 15.7344
LC-1/sq GDSC2 1.9373 8.5472 -1.607 18.246
HOP-92 GDSC2 1.94 7.6699 -1.1669 15.923
A-427 GDSC2 1.9715 10.0017 -2.3058 21.4352
NCI-H2141 GDSC2 1.9962 4.8646 0.274 7.174
NCI-H250 GDSC2 2.0715 8.3421 -1.3972 16.7879
HCC827 GDSC2 2.1355 6.2739 -0.318 10.4688
SK-MES-1 GDSC2 2.2004 8.306 -1.2774 15.7989
NCI-H1915 GDSC2 2.2361 7.4557 -0.827 13.2084
NCI-H2591 GDSC2 2.2693 7.8581 -1.0011 14.1039
ABC-1 GDSC2 2.3019 7.4002 -0.7489 12.5874
NCI-H358 GDSC2 2.3475 7.3769 -0.7026 12.2018
NCI-H2405 GDSC2 2.3675 10.7853 -2.3804 20.6644
NCI-H1963 GDSC2 2.3817 5.6558 0.1692 6.8849
IA-LM GDSC2 2.4233 4.5265 0.7403 3.3449
NCI-H196 GDSC2 2.43 4.4829 0.7652 3.1863
NCI-H1355 GDSC2 2.4883 5.2385 0.4451 4.9726
NCI-H1581 GDSC2 2.5633 6.3094 -0.0199 7.6171
NCI-H2135 GDSC2 2.5939 4.5347 0.8419 2.4549
NCI-H2803 GDSC2 2.5954 7.841 -0.7461 11.8285
NCI-H1666 GDSC2 2.6094 9.3213 -1.4662 15.7084
NCI-H2818 GDSC2 2.6595 11.4316 -2.474 20.294
VMRC-LCD GDSC2 2.6992 5.2497 0.577 3.7756
NCI-H2087 GDSC2 2.715 6.6391 -0.0736 7.5989
NCI-H1563 GDSC2 2.7893 12.0305 -2.6712 20.778
EKVX GDSC2 2.8055 6.4332 0.0871 6.4484
NCI-H345 GDSC2 2.8324 3.7981 1.2676 0.2508
NCI-H727 GDSC2 2.8388 6.4578 0.0976 6.3164
NCI-H650 GDSC2 3.0622 11.5059 -2.2047 18.111
NCI-H441 GDSC2 3.0649 10.3203 -1.6191 15.3485
NCI-H1993 GDSC2 3.0688 4.943 0.9219 1.3849
NCI-H524 GDSC2 3.0889 10.0186 -1.4536 14.4595
NCI-H1299 GDSC2 3.2165 10.5672 -1.6297 15.04
NCI-H841 GDSC2 3.2504 9.6383 -1.1524 12.5176
NCI-H720 GDSC2 3.2584 4.5512 1.1603 0.3338
NCI-H1568 GDSC2 3.4302 12.47 -2.4068 18.1129
DMS 114 GDSC2 3.4845 11.4973 -1.8911 15.675
KNS-62 GDSC2 3.59 9.9189 -1.0527 11.2424
NCI-H1435 GDSC2 3.7393 5.2745 1.0848 0.3141
LK-2 GDSC2 3.7398 17.6582 -4.7341 25.4137
NCI-H1755 GDSC2 3.7517 5.5808 0.9777 0.5969
RERF-LC-KJ GDSC2 3.8326 5.4322 1.0639 0.326
Lu-165 GDSC2 3.959 6.4932 0.7141 1.3903
HCC15 GDSC2 3.9697 16.6 -4.0397 22.8851
NCI-H2869 GDSC2 4.0015 15.1607 -3.3095 20.363
NCI-H1869 GDSC2 4.4928 6.5659 0.9096 0.4246
COR-L105 GDSC2 5.3039 17.3528 -3.4562 18.2277
⏷ Show the Full List of 129 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC2 -1.7721 0.8974 -1.9165 34.3814
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-510 GDSC2 -3.7139 0.9305 -4.0331 52.6237
EC-GI-10 GDSC2 -2.7259 3.1456 -3.6221 45.0804
KYSE-180 GDSC2 -1.2314 6.0996 -3.3017 36.5215
KYSE-410 GDSC2 0.396 3.207 -0.3485 16.1896
TE-15 GDSC2 0.4229 4.6077 -0.9779 19.7674
OE33 GDSC2 0.5222 4.6235 -0.8908 18.9072
TE-1 GDSC2 0.7717 4.2578 -0.4777 15.5842
OE21 GDSC2 1.2504 4.1149 0.0314 10.8459
TE-4 GDSC2 1.5645 4.0039 0.3584 7.8243
TE-5 GDSC2 1.6883 4.1249 0.4 7.206
KYSE-270 GDSC2 1.698 5.1302 -0.0944 10.284
OE19 GDSC2 1.7501 3.1291 0.9458 3.5917
TE-6 GDSC2 2.0048 6.3303 -0.4475 11.598
KYSE-520 GDSC2 2.0578 14.3373 -4.4016 28.4949
TE-9 GDSC2 2.0923 4.6781 0.4381 5.911
COLO 680N GDSC2 2.1413 6.1563 -0.2552 10.0728
KYSE-140 GDSC2 2.4312 6.4166 -0.167 8.8144
TE-8 GDSC2 2.4846 9.1195 -1.4613 16.0066
KYSE-70 GDSC2 4.4537 6.1968 1.0245 0.2113
KYSE-450 GDSC2 4.5161 15.4174 -3.067 18.3753
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A2780 GDSC2 -4.9155 1.4683 -5.4777 60.4626
TOV-112D GDSC2 -2.9791 -0.2948 -3.036 45.9429
OVCAR-8 GDSC2 -2.6294 1.9414 -3.1164 43.6019
OVCAR-5 GDSC2 -1.6057 4.4474 -2.9485 37.3008
IGROV-1 GDSC2 -1.5165 4.8596 -3.0339 37.1067
OVTOKO GDSC2 -1.0269 5.3436 -2.7511 33.9124
OAW42 GDSC2 -0.855 5.1951 -2.5107 32.2822
DOV13 GDSC2 -0.6924 1.9811 -1.0189 24.5791
ES-2 GDSC2 -0.3257 5.5031 -2.1288 28.481
OAW28 GDSC2 0.1939 6.4119 -2.0673 26.1731
SK-OV-3 GDSC2 0.3911 7.9618 -2.6459 27.863
OV56 GDSC2 0.3927 4.8081 -1.103 20.5802
TYK-nu GDSC2 0.5663 7.2535 -2.1374 25.1327
OVCAR-4 GDSC2 0.7831 4.5539 -0.6112 16.3438
OVISE GDSC2 0.925 3.1578 0.1982 10.9071
TOV-21G GDSC2 1.3313 9.0907 -2.3813 23.6633
EFO-27 GDSC2 1.7392 3.9873 0.5098 6.3717
OVK18 GDSC2 1.8577 6.471 -0.6346 13.1202
OVCAR-3 GDSC2 2.018 4.8911 0.2775 7.097
EFO-21 GDSC2 2.272 8.2711 -1.2042 15.2123
OV-90 GDSC2 2.962 5.2005 0.7548 2.3528
Kuramochi GDSC2 3.311 6.5556 0.3481 4.0043
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MIA PaCa-2 GDSC2 -1.5757 3.2223 -2.4175 35.3956
CFPAC-1 GDSC2 -1.4742 3.9687 -2.61 35.5604
KP-4 GDSC2 -0.6384 2.7237 -1.2256 25.4418
PSN1 GDSC2 -0.1839 3.5379 -1.0866 22.7426
PaTu 8988t GDSC2 -0.0013 6.6683 -2.3753 28.2327
PL4 GDSC2 0.2071 5.0686 -1.4058 22.9097
YAPC GDSC2 0.4025 6.4907 -1.9116 24.69
DAN-G GDSC2 0.7633 3.9434 -0.3336 14.7416
Capan-1 GDSC2 0.9498 5.1172 -0.7349 16.5071
HuP-T4 GDSC2 1.083 10.6566 -3.3756 28.1793
QGP-1 GDSC2 1.3098 8.2836 -1.9963 22.0182
HPAC GDSC2 1.7014 4.0742 0.436 6.9419
BxPC-3 GDSC2 1.739 3.6873 0.6592 5.4286
HuP-T3 GDSC2 1.7729 7.3114 -1.1231 16.161
SUIT-2 GDSC2 1.906 4.531 0.3702 6.805
KP-1N GDSC2 2.0369 5.3405 0.0692 8.3458
HPAF-II GDSC2 2.0472 4.3554 0.5635 5.2405
PaTu 8902 GDSC2 2.0542 6.9334 -0.709 13.0138
Capan-2 GDSC2 2.1942 5.1239 0.2939 6.5594
Panc 08.13 GDSC2 2.542 5.0605 0.5654 4.1449
Panc 02.03 GDSC2 2.8548 13.3207 -3.2611 22.8657
AsPC-1 GDSC2 3.1238 8.2094 -0.5491 9.4784
Panc 10.05 GDSC2 3.1812 11.2659 -1.9982 16.885
SU.86.86 GDSC2 3.4359 4.9831 1.0719 0.4925
KP-2 GDSC2 3.4403 6.5729 0.4148 3.4404
KP-3 GDSC2 3.7266 5.741 0.9062 0.8494
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC2 -2.1633 4.0997 -3.3884 41.356
IST-Mes1 GDSC2 -0.3695 8.7319 -3.7243 34.1517
MPP 89 GDSC2 1.7725 4.0982 0.481 6.4622
NCI-H28 GDSC2 2.641 9.3139 -1.4386 15.4858
NCI-H2052 GDSC2 3.4144 10.7716 -1.5874 14.3723
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC2 -3.8446 1.8776 -4.4229 53.3286
22Rv1 GDSC2 0.2488 9.2685 -3.4201 31.0512
VCaP GDSC2 0.5228 8.2242 -2.6567 27.4421
PC-3 GDSC2 0.6544 7.1055 -1.9846 24.1324
DU145 GDSC2 2.0634 4.8922 0.3112 6.7723
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC2 -0.8683 2.7497 -1.481 27.8059
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LOX-IMVI GDSC2 -3.8072 2.4082 -4.5435 52.9032
RPMI-7951 GDSC2 -3.1207 3.2623 -4.0896 48.0699
A-375 GDSC2 -2.1605 2.1573 -2.672 39.5037
M14 GDSC2 -1.2603 5.5735 -3.0905 36.0543
A2058 GDSC2 -0.7279 4.4298 -2.037 29.7952
HT-144 GDSC2 -0.7128 9.5827 -4.4598 37.1567
WM35 GDSC2 -0.3025 4.174 -1.4908 25.3766
WM278 GDSC2 -0.1785 3.0959 -0.8905 21.6307
G-mel GDSC2 0.1379 2.949 -0.4992 18.0952
G-361 GDSC2 0.1616 4.4491 -1.1559 21.745
A101D GDSC2 0.265 4.6716 -1.1606 21.3756
IGR-37 GDSC2 1.0251 6.5528 -1.3797 19.8709
HMV-II GDSC2 1.1232 5.9426 -0.9897 17.4084
COLO 679 GDSC2 1.1467 8.2463 -2.1176 23.0921
WT2-iPS GDSC2 1.156 7.0143 -1.495 20.0464
COLO 829 GDSC2 1.204 11.6589 -3.7729 29.0668
SK-MEL-24 GDSC2 1.3716 8.3775 -1.9907 21.7983
GAK GDSC2 1.6257 3.3529 0.7347 5.2663
UACC-62 GDSC2 1.87 4.434 0.3905 6.772
SH-4 GDSC2 1.915 6.1862 -0.4467 11.8382
WM115 GDSC2 2.3345 5.9904 -0.0286 8.206
SK-MEL-5 GDSC2 2.4191 6.1616 -0.0509 8.1395
COLO 792 GDSC2 2.5754 12.3923 -3.0171 22.6791
CHL-1 GDSC2 2.884 8.854 -1.032 12.7246
WM1552C GDSC2 2.9532 10.831 -1.9532 17.2313
IGR-1 GDSC2 2.9915 10.801 -1.9098 16.9332
CP66-MEL GDSC2 2.9958 8.7924 -0.9214 11.8544
SK-MEL-2 GDSC2 3.03 4.0653 1.2475 0.2152
Mel JuSo GDSC2 3.2459 11.433 -2.0327 16.8898
WM793 GDSC2 3.6247 9.5939 -0.8737 10.2133
UACC-257 GDSC2 3.7036 5.0456 1.1522 0.188
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC2 -1.4372 4.4373 -2.7693 35.9075
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
G-401 GDSC2 -3.892 3.2935 -4.9327 53.1826
EW-8 GDSC2 -2.8403 -0.1303 -2.9067 44.6079
SK-LMS-1 GDSC2 -1.9187 3.1299 -2.7491 38.3553
SW982 GDSC2 -1.3008 4.342 -2.5872 34.6265
GCT GDSC2 -1.275 3.8538 -2.3536 33.6411
VA-ES-BJ GDSC2 -0.8586 4.4227 -2.1672 30.9373
MES-SA GDSC2 -0.7505 4.3569 -2.0276 29.8543
RD GDSC2 -0.3262 3.1257 -1.0572 23.1759
SW872 GDSC2 -0.2009 3.5079 -1.0909 22.8366
KYM-1 GDSC2 0.1671 2.7759 -0.3953 17.3725
G-402 GDSC2 0.2568 7.0809 -2.3356 27.1001
Rh30 GDSC2 0.6241 1.7994 0.4708 10.4662
A-204 GDSC2 0.655 7.8667 -2.361 25.79
SK-UT-1 GDSC2 0.8007 5.2091 -0.916 18.0666
Rh41 GDSC2 0.9262 5.3868 -0.8895 17.4864
HT-1080 GDSC2 1.5053 3.9563 0.3323 8.1645
SW684 GDSC2 2.227 6.0844 -0.1547 9.2413
RKN GDSC2 2.7488 5.2079 0.627 3.3991
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NUGC-3 GDSC2 -2.3795 1.4278 -2.6997 40.928
AGS GDSC2 -2.3037 1.9006 -2.7491 40.6018
MKN45 GDSC2 -2.2443 2.1037 -2.7464 40.2314
SNU-1 GDSC2 -2.2338 3.9207 -3.3911 41.7545
SNU-5 GDSC2 -1.9034 1.8421 -2.2952 36.7056
RF-48 GDSC2 -0.8158 7.69 -3.6429 35.6632
MKN1 GDSC2 -0.1356 6.3205 -2.3345 28.5863
HGC-27 GDSC2 -0.0717 4.4812 -1.4007 23.9708
RERF-GC-1B GDSC2 -0.0371 3.5424 -0.9384 21.3205
23132/87 GDSC2 0.0531 4.9528 -1.4995 23.9883
IM95 GDSC2 0.5367 5.1703 -1.1419 20.2693
NUGC-4 GDSC2 0.8271 4.164 -0.3802 14.8007
GCIY GDSC2 0.8628 5.5946 -1.0495 18.6118
ECC10 GDSC2 1.0697 7.1253 -1.6255 20.9939
NCI-N87 GDSC2 1.1316 7.3757 -1.6963 21.1459
Hs 746.T GDSC2 1.5356 15.1022 -5.2149 31.8632
SK-GT-2 GDSC2 1.572 5.2334 -0.2501 11.6137
OCUM-1 GDSC2 2.0996 6.5877 -0.5015 11.6672
KATO III GDSC2 2.4903 4.8774 0.6183 3.934
MKN28 GDSC2 2.7542 8.2778 -0.8441 11.9967
SNG-M GDSC2 2.1801 5.6918 0.004 8.3853
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
FTC-133 GDSC2 -1.5654 3.6711 -2.5841 35.9349
ASH-3 GDSC2 -1.4961 2.3928 -2.0282 33.429
IHH-4 GDSC2 -1.2437 2.552 -1.8113 31.1902
TT2609-C02 GDSC2 -0.4655 6.9134 -2.9348 32.1445
CAL-62 GDSC2 -0.0692 3.6661 -1.0262 21.9407
8505C GDSC2 0.7963 3.984 -0.3218 14.5537
BHT-101 GDSC2 1.6493 6.8602 -0.9993 15.8319
K5 GDSC2 1.7409 8.1025 -1.5448 18.4992
HTC-C3 GDSC2 2.5731 6.292 -0.0045 7.5019
B-CPAP GDSC2 2.6445 10.2258 -1.8873 17.7005
8305C GDSC2 3.1217 10.0533 -1.4468 14.3471
WRO GDSC2 3.3592 7.5542 -0.0824 6.3346
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BICR 22 GDSC2 -3.5626 1.5594 -4.0258 51.3068
SAS GDSC2 -0.9462 2.5312 -1.4833 28.1785
CAL-33 GDSC2 -0.8909 7.5384 -3.6428 35.9672
HO-1-N-1 GDSC2 -0.4312 2.6254 -0.9666 23.13
SKN-3 GDSC2 -0.2786 2.7798 -0.8653 21.9114
BICR 10 GDSC2 -0.1111 5.1848 -1.7691 25.9725
Detroit 562 GDSC2 0.0098 4.6548 -1.4013 23.6505
CAL-27 GDSC2 0.6068 5.055 -1.0201 19.3382
DOK GDSC2 0.664 5.8134 -1.3385 20.8831
HSC-2 GDSC2 0.7966 3.901 -0.2814 14.3067
BB49-HNC GDSC2 0.8075 10.9246 -3.7476 30.2028
NCI-H3118 GDSC2 0.8449 7.2526 -1.887 23.0212
HSC-3 GDSC2 0.8993 3.9029 -0.1854 13.3603
FaDu GDSC2 0.9128 7.2764 -1.8387 22.562
SAT [Human HNSCC] GDSC2 1.1492 4.8796 -0.4382 14.0733
OSC-20 GDSC2 1.8656 7.0501 -0.9174 14.7408
SCC-15 GDSC2 1.8927 4.4953 0.3777 6.7926
UPCI-SCC-090 GDSC2 2.0739 11.8658 -3.1539 24.5223
HSC-4 GDSC2 2.2628 6.5972 -0.3811 10.5217
PCI-04B GDSC2 2.334 4.3885 0.7475 3.4788
BICR 78 GDSC2 2.4154 8.8575 -1.3845 15.7897
Ca9-22 GDSC2 2.5837 5.9435 0.1714 6.4174
SCC-9 GDSC2 3.1605 11.0298 -1.8974 16.4644
JHU-022 GDSC2 3.6363 10.8265 -1.458 13.2322
LB771-HNC GDSC2 3.7016 11.5927 -1.7835 14.6777
SCC-4 GDSC2 3.7325 5.9095 0.8431 1.0774
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-29 GDSC2 -2.0746 1.6558 -2.4284 38.181
BFTC-905 GDSC2 -0.8889 2.3862 -1.3694 27.3317
RT-4 GDSC2 -0.6042 4.0574 -1.7458 27.9198
KU-19-19 GDSC2 0.332 5.3808 -1.4369 22.6024
639V GDSC2 0.4179 3.2289 -0.3364 16.0335
TCCSUP GDSC2 0.9581 5.5641 -0.9485 17.718
RT-112 GDSC2 0.9953 9.5522 -2.9001 26.7893
647V GDSC2 1.0427 4.3276 -0.2609 13.338
SW780 GDSC2 1.5961 5.24 -0.2332 11.4388
5637 GDSC2 1.6455 6.0924 -0.6185 13.6329
J82 GDSC2 1.6654 3.8745 0.5065 6.5977
HT-1197 GDSC2 1.9198 3.9257 0.6806 4.8232
SW1710 GDSC2 2.85 5.5354 0.538 3.7267
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NEC8 GDSC2 -3.5063 -1.4148 -3.5153 51.08
ME-180 GDSC2 -3.4053 -0.6762 -3.4492 50.0749
PA-1 GDSC2 -2.464 5.45 -4.2674 44.4079
DSH1 GDSC2 -2.3816 1.7944 -2.8028 41.2394
SiSo GDSC2 -1.7485 3.8602 -2.8538 37.7544
PWR-1E GDSC2 -1.6041 1.8343 -1.9666 33.721
C-33 A GDSC2 -1.2098 2.152 -1.6367 30.1957
SKG-IIIa GDSC2 -0.5406 5.0463 -2.128 29.3756
HEY GDSC2 -0.2709 4.6582 -1.6805 26.1917
CAL-39 GDSC2 -0.1541 5.1831 -1.8102 26.34
HEC-1 GDSC2 -0.0995 2.5102 -0.5686 19.4776
TC-YIK GDSC2 0.098 1.5455 -0.0272 15.5797
PEO1 GDSC2 0.6322 3.7321 -0.3584 15.3626
Ca Ski GDSC2 0.7443 6.0978 -1.4054 20.9566
SW756 GDSC2 1.1659 11.9331 -3.9423 29.6799
DoTc2 4510 GDSC2 1.3146 4.6692 -0.1879 12.0095
OVCA420 GDSC2 1.4176 3.4647 0.5023 7.3573
HT-3 GDSC2 1.7728 5.5555 -0.246 11.0111
HeLa GDSC2 2.1226 10.8107 -2.5879 22.2055
MS751 GDSC2 2.1794 4.6649 0.5079 5.2721
SKN GDSC2 2.2495 4.2057 0.7785 3.4666
BPH-1 GDSC2 2.297 12.5154 -3.2988 24.4356
OVMIU GDSC2 2.3389 8.409 -1.2209 15.1237
LB831-BLC GDSC2 2.3508 9.1517 -1.5806 16.9694
SiHa GDSC2 2.6879 7.4914 -0.5072 10.225
C-4-I GDSC2 2.7744 5.0304 0.7235 2.8133
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mitoxantrone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Accelerated clearance of Mitoxantrone due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [16]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Mitoxantrone and Roflumilast. Asthma [CA23] [16]
Sparfloxacin DMB4HCT Minor Decreased absorption of Mitoxantrone due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [17]
ABT-492 DMJFD2I Minor Decreased absorption of Mitoxantrone due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [17]
Fostemsavir DM50ILT Moderate Decreased clearance of Mitoxantrone due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [18]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Mitoxantrone and Teriflunomide. Hyper-lipoproteinaemia [5C80] [19]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Mitoxantrone and Denosumab. Low bone mass disorder [FB83] [20]
Lasmiditan DMXLVDT Moderate Decreased clearance of Mitoxantrone due to the transporter inhibition by Lasmiditan. Migraine [8A80] [21]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Mitoxantrone and Tecfidera. Multiple sclerosis [8A40] [22]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Mitoxantrone and Siponimod. Multiple sclerosis [8A40] [23]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Mitoxantrone and Fingolimod. Multiple sclerosis [8A40] [24]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Mitoxantrone and Ocrelizumab. Multiple sclerosis [8A40] [25]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Mitoxantrone and Ozanimod. Multiple sclerosis [8A40] [16]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Mitoxantrone and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [26]
Enzalutamide DMGL19D Moderate Accelerated clearance of Mitoxantrone due to the transporter induction by Enzalutamide. Prostate cancer [2C82] [27]
Darolutamide DMV7YFT Moderate Decreased clearance of Mitoxantrone due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [28]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Mitoxantrone and Canakinumab. Rheumatoid arthritis [FA20] [29]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Mitoxantrone and Rilonacept. Rheumatoid arthritis [FA20] [29]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Mitoxantrone and Golimumab. Rheumatoid arthritis [FA20] [30]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Mitoxantrone when combined with Anthrax vaccine. Sepsis [1G40-1G41] [31]
Eltrombopag DMOGFIX Moderate Decreased clearance of Mitoxantrone due to the transporter inhibition by Eltrombopag. Thrombocytopenia [3B64] [32]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Mitoxantrone and Valganciclovir. Virus infection [1A24-1D9Z] [23]
⏷ Show the Full List of 22 DDI Information of This Drug

References

1 Mitoxantrone FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7242).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
9 A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33.
10 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
11 Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol. 2006 Apr;69(4):1499-505.
12 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
13 FDA label of Mitoxantrone. The 2020 official website of the U.S. Food and Drug Administration.
14 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
15 Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016 Nov;90(11):2763-2777.
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
18 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
19 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
20 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
21 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
22 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
23 Cerner Multum, Inc. "Australian Product Information.".
24 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
25 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
26 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
27 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
28 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
29 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
30 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
31 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
32 Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]